

Review Article

A Review on Health Benefits of Medicinal Mushroom *Agaricus Subrufescens*

MAURYA MANGLA*, CHANDRA SURESH, SAHU SHACHI

Department of Pharmacology, Pranveer Singh Institute of Technology, Bhauti-Kanpur 208020, India

ARTICLE DETAILS

Article history:
Received on 02 February 2013
Modified on 20 March 2013
Accepted on 25 March 2013

Keywords:

Agaricus subrufescens,
Allergy,
Cancer,
Inflammation,
Immunomodulation,
Agartine.

ABSTRACT

Medicinal mushrooms have currently become an important issue due to their various therapeutic properties. Of these, *Agaricus subrufescens*, formerly named *A. blazei* Murrill, has been used as dietary mushroom and to formulate nutraceuticals and functional foods. Since its discovery in 1893, this mushroom has been cultivated throughout the world, especially in Brazil where several strains of *A. subrufescens* have been developed. This mushroom is rich in the immunomodulating polysaccharides, β -glucans, and has been shown to have antitumor, anti-infection, and antiallergic/-asthmatic properties in mouse models, in addition to anti-inflammatory effects in inflammatory bowel disease patients. This article presents up-to-date information on this mushroom including its taxonomy and health promoting benefits. Medicinal properties of *A. subrufescens* are emphasized in several studies which are reviewed here.

© KESS All rights reserved

INTRODUCTION

The uses of mushrooms as nutritional or therapeutic bases were sometimes daily or even decisive in human progress. They usually exhibit special fragrance and texture [1]. *Agaricus subrufescens* (incorrectly known as *Agaricus blazei*, *Agaricus blazei* Murrill, *Agaricus brasiliensis*, *Agaricus sylvaticus* or *Agaricus rufotegulis*) is a species of mushroom, commonly known as Almond mushroom, Mushroom of the Sun, God's Mushroom, Mushroom of Life, Royal Sun Agaricus, Jisongrong or Himematsutake (Japanese; "princess matsutake") and by a number of other names [2,3]. *Agaricus subrufescens* is a choice edible, with a somewhat sweet taste and fragrance of almonds. This mushroom is also well known as a medicinal mushroom, for its purported medicinal properties, due to research which indicates it may stimulate the immune system [4]. Higher fungi have been used by mankind for millennia. Firstly, they are used as part of regular diet for their nutritional value, completing population food intake. They contain minerals, vitamins & nutritive such as proteins, polysaccharides & have low fat content. Secondary, mushrooms fruiting bodies are also appreciated for delicacy. Thirdly, higher fungi are used for medicinal purpose.

Their pharmacological action and therapeutic interest in promoting human health are also known for thousands of years. This mushroom has been used as a medicinal food for the prevention of cancer, diabetes, hyperlipidemia, arteriosclerosis, and chronic hepatitis and is known to impact putatively the immune system [5]. Potential effective compounds of this mushroom can be isolated either from their fruiting bodies, or even from pure culture of mycelia and culture broth filtrate.

Agaricus subrufescens often occurs in domesticated or semi disturbed habitats, including leaf piles. It has been recognized occasionally growing "wild" outside northeastern North America, for example in California [6], Israel, Taiwan [7] and Hawaii, where it grows under forest trees.

The aim of this present paper is to summarize the available information on *A. subrufescens*, including its taxonomy, phylogeny, distribution, various health benefits and current status of scientific research.

CHARACTERISTICS AND TAXONOMY

A. subrufescens Peck is a gilled fungus belonging to the family of the Agaricaceae in the order Agaricales [9] within the phylum Basidiomycota. It is a saprobe and inhabits rotting leaves often at the borders between forests and parks. The

*Author for Correspondence:

Email: manglamaurya13@gmail.com

basidiomata morphology of this species is variable. Sporocarps can be robust or gracile, both due to the genotype and environmental influences [3]. The cap is 20–70 mm broad in button stage and 60–150 mm broad in mature stage hemispherical to convex to plano-convex shape and fleshy. The surface is dry and covered by fibrillose squamulose hairs. The pileus color is somewhat variable and sensible to the light, ranging from brownish-gold, reddish brown, purple brown to brownish orange, more or less pale and sometimes completely white. The basidiospores are chocolate brown ($5.4 \mu\text{m}$) [9, 10]. The specimens from Thailand differ from those previously reported in terms of size, sturdiness and length of stipe, which were larger, more virgate and fragile than those found in America; their cap color is more reddish than those of the European taxa. The stipe is also highly variable which could be short and firm or more slender and virgate [3]. However, the cap shape and lamellae color were in concordance with those reported by Firenzuoli et al. (2008) from Brazil. The small cottony floccules beneath the remnant partial veil are a consistent character of the species. This important feature is also found in Thai taxa. The morphological variability of this species may be influenced by different climates and ecosystem.



Figure 1: *Agaricus subrufescens*. (A) Basidiocarp, (B) Schaeffer's cross-reaction on pileus

Agaricus subrufescens was first described by the American botanist Charles Horton Peck in 1893 [11]. During the late 19th and early 20th century, it was cultivated for the table in the eastern United States [3]. It was discovered again in Brazil during the 1970s, and misidentified as *Agaricus blazei* Murrill, a species originally described from Florida. It was soon marketed for its purported medicinal properties under various names, including *ABM* (for *Agaricus blazei* Murrill), *Cogumelo do Sol* (mushroom of the sun), *Cogumelo de Deus* (mushroom of God), *Cogumelo de Vida* (mushroom of life), *Himematsutake*,

Royal Sun Agaricus, *Mandelpilz*, and *Almond Mushroom*.

In 2002, Didukh and Wasser correctly rejected the name *A. blazei* for this species, but unfortunately called the Brazilian fungus *A. brasiliensis* [2] a name that had already been used for a different species, *Agaricus brasiliensis* Fr. (1830). Richard Kerrigan undertook genetic and interfertility testing on several fungal strains and showed that samples of the Brazilian strains called *A. blazei* and *A. brasiliensis* were genetically similar to, and interfertile with, North American populations of *Agaricus subrufescens*. These tests also found European samples called *A. rufotegulis* to be of the same species. Because *A. subrufescens* is the oldest name, it has taxonomical priority.

CHEMICAL COMPOSITION

The average composition of mushrooms is normally 90% water, 2-40% protein, 2-8% fat, 1-55% carbohydrate, 3-32% fiber, yielding 8-10% ash [12]. Several categories of molecules are supposed to be involved in beneficial effects and most of the molecules categories found in *A. subrufescens* (*A. blazei* Murrill) are common to the entire fungal kingdom. Active compounds found in *A. blazei* are listed in Table 1. The active compounds isolated from *A. subrufescens* are believed to be mainly polysaccharides [13-16] β -glucan [17-19, 22] and glucomannan [20-22] or riboglucan [24] (Table 1). Additionally, in *A. blazei*, a protein (or glycoprotein), Glucan protein complex, a lectin [23, 24] originally found associated to β (2, 25) -glucan, were characterized and claimed to be anti-tumor (Table 1). Recently, it has been shown that *A. blazei* sp do contain aromatic hydrazines, especially agaritine [26] (Table 1) and its derivatives [27] More recently, blazein a steroid derivative found in *A. blazei* (*A. subrufescens*), was shown to kill Human lung cancer LU99 cells but not normal Human lymphocyte [28]. Agaritine extracted from *A. blazei* was also showed to kill leukemic cell in vitro. Its cytotoxicity is triggered cell apoptosis with an IC50 in the range of 2.7 to 16 $\mu\text{g} / \text{ml}$ depending on the cell line [29, 30]. Agaritine is found at similar concentration in both *A. blazei* and *A. bisporus* (approximately 1.8 mg/g dry weight) [27].

Blazein (named after the synonym *A. blazei*) is a steroid derivative found in *A. subrufescens* with an in vitro anti-cancer activity on human lung cancer LU99 cells without affecting normal human lymphocytes [29].

Table 1: Bioactive compound from Agaricus subrufescens

Bioactive Compounds	Main Potential Effects	Reference
Polysaccharides		
β-(1,6)-glucan	Immuno-active involved in anti tumour effect and/or prevention; antimicrobial	[13], [14], [15], [16]
α-(1,4)-; β-(1,6)-glucan		[14]
α-(1,6)-; α-(1,4)-glucan		[17], [18]
β-(1,6)-; β-(1,3)-glucan		[19]
β-(1,6)-; α-(1,3)-glucan		[19]
Glucomannan		[19]
β-(1,2)- β-(1,3)-glucomannan	[20], [21], [22], [15]	
Glucan-Protein complex	Oncogenesis prevention	[14], [17], [18]
Lectin	Anti-tumour	[23]
Riboglucan	Anti-tumour	[24]
Ergosterol	Anti-tumour	[5]
Sodium pyroglutamate	Anti-tumour	[31]
RNA-protein complex	Anti-tumour	[32]
Agaritrine	Anti-tumour	[26]
Blazein	Anti-tumour	[28]




Figure 2: Role of agaricus blazei murill in cancer attacks

PHARMACEUTICAL PROPERTIES

A. subrufescens is a well-known medicinal mushroom used in many countries, and thus consumption of this mushroom is used as an alternative way to cure diseases. Various pharmaceutical activities have been found associated with A. subrufescens and researches to reveal the function of bioactive compounds

are extensive. Recent studies have been performed in vitro and in vivo to confirm the mushrooms therapeutic properties [9]. Identification of (novel) immunomodulating bioactive compounds from the mushroom may also help in new treatments for patients suffering from cancer and immunodeficiency [33].

ANTI-CANCER AND TUMOR SUPPRESSIVE ACTIVITY

There have been many studies showing the anti-tumor activity of *A. subrufescens* [9]. In the last decade, many bioactive substances (Table 1) have been shown to exhibit the potential anti-tumor properties. The major anti-tumor substances from *A. subrufescens* are polysaccharide-enriched extracts and protein-bound polysaccharide complexes [34-36]. Mushroom polysaccharides prevent oncogenesis, show direct antitumor activity against various synergetic tumors, and prevent tumor metastasis. Their activity is especially beneficial when used in conjunction with chemotherapy. The antitumor action of polysaccharides requires an intact T cell component; their activity is mediated through a thymus-dependent immune mechanism. They activate cytotoxic macrophages, monocytes, neutrophils, natural killer cells, dendritic cells, and chemical messengers (cytokines, such as interleukins, interferons, and colony stimulating factors) that trigger complementary and acute phase responses. Also, mushroom polysaccharides can be considered as multicytokine inducers able to induce gene expression of various immunomodulatory cytokines and cytokine receptors [13, 37-44].

The anti-tumor mechanisms of *A. subrufescens* extracts have been shown by oral administration in different laboratory mice models such as Sarcoma 180-implanted bearing mice [5], Meth-A fibrosarcoma tumor-bearing mice [34, 23, 19, 35, 17, 5] and BALB/c nu/nu mice implanted leukemic model [45, 46] extracted the polysaccharide complex from *A. subrufescens* and characterized a glucan-protein complex by FTIR, 13C NMR and 1H NMR spectroscopy. The extract exhibits both of α and β glycosidic linkage of glucans. The result indicates that β -glucans are the predominant structures as compared to α -glucans. Moreover, it also can increase the antitumor activity of other chemotherapeutics.¹⁸ A new class of antitumor medicinal mushroom drugs has been called biological response modifiers (BRMs). The application of BRMs has become the new kind of cancer treatment together with surgery, chemotherapy, and radiotherapy [13, 47-49].

ANTI-GENOTOXICITY ACTIVITIES

Some in vitro and in vivo genotoxic studies (e.g. DNA damage and aberration tests) have been performed on chemical carcinogenesis models.

In a in vitro study by Angeli et al., [50] the authors suggested that β -glucan present in *A. subrufescens* has no genotoxic or mutagenic effect, but protects the damaged DNA (Deoxyribonucleic acid) caused by benzopyrene in test protocols. Results indicate that the β -glucan works through a link with benzopyrene by capturing free radicals during their activation. To investigate the possible antimutagenic effect of *A. subrufescens* in vivo, Delmanto et al. [51] evaluated its effect on clastogenicity induced by Cyclophosphamide (CP) in mice, using the micronucleus test in bone marrow (MNPCE) and in peripheral blood (MNRET). Male Swiss mice were treated with CP (25 or 50mg/kg i.p.) or with CP plus mushroom solution at three different temperatures: 4, 21, and 60 degrees C. Aqueous solution of a mixture from various lineages of the mushroom inhibited induction of micronuclei by CP in bone marrow and in peripheral blood of mice. In contrast to the mixture of lineages, a single isolated lineage did not lead to a reduction of CP-induced MN frequencies in either bone marrow or blood cells of mice. The results suggest that under certain circumstances these mushrooms exhibit antimutagenic activities that might contribute to an anticarcinogenic effect.

BIOLOGICAL ACTIVITIES ON THE IMMUNE SYSTEM

The immunostimulants and immunomodulatory activity of both mycelial and fruiting bodies of *A. subrufescens* using water and ethanol extracts have been demonstrated in many in vitro experiments, although not always the results are concordant, but sometimes contradictory. Water extracts of the mycelial culture and fruiting bodies such as fractions B-4, B-5 obtained from ethanol precipitation (respectively 44% and 50%) of fruiting bodies, markedly induced TNF production and IL-8 of macrophages derived from rat bone-marrow [52]. Other extracts containing lignin-based derivatives have shown the induction of TNF-g, IL-8 and nitric oxide secretion by macrophages [53], anti-viral activity of different viruses [54], and direct anticancer activity [55]; so lignin derivatives apparently have more different and important pharmacological activities. Fine particles of *A. subrufescens* fruiting body and mycelium, respectively, prepared by mechanical disruption, activated the human complement system via the alternative pathway in human serum, is another proof of its activity in enhancing natural immunity in bacterial infections [56]. From these studies it is

clear that the *A. subrufescens* fractions act on many different biological receptors of the immune system.

CYTOKINE INDUCTION

A. subrufescens is shown to stimulate cytokine production, such as interleukin-12 [57], interferon- γ and natural killer (NK) activity. The water-soluble extracts (proteo-glucans) from crude *A. subrufescens* up regulate the in vitro maturation of dendritic cells [58, 59]. Ex vivo experiment on total heparinised blood of volunteers and in vitro experiment show that the monocytes-derived dendritic cells from peripheral blood mononuclear cells produce an increase level of cytokine and chemokines. The most abundant cytokines after *A. subrufescens* stimulation were mainly pro-inflammatory cytokine and chemokines IL-8, G-CSF, TNF- α , IL-1 β , IL-6, IL 17 and MIP-1 β .

The inhibition of pro-inflammatory cytokines appears to be dose dependant [60]. This is in contradiction with most of the tests made in murine models with different *A. blazei* extracts. This contradiction can be explained only by the capacity of certain glucans to cross the murine intestinal barriers. Ex vivo experiment with healthy volunteers heparinised blood controversially showed stimulation of all pro-inflammatory cytokines tested as expected. More recently, a clinical test with patients suffering of inflammatory bowel disease (IBD) inflammatory disease of colon and intestine has been conducted [59]. Patients with Chron's disease (CD) widely regarded as an autoimmune disease, and ulcerative colitis (UC) were exposed orally to *A. blazei* enriched mixture (AndoSan). After 12 days ingestion, the *A. blazei* extract promotes in these patients anti-inflammatory effects with no side effect.

IMMUNOLOGIC INTERVENTION

The specific mechanisms that contribute to an enhanced state of immunity remain partially understood. Recent insights in two rapidly expanding fields, the cytokine mediated homeostasis of mature lymphocytes by cytokines, such as interleukins and autoreactive T cells by CD4⁺CD25⁺ regulatory T cells, provide the foundation for what might be occurring. Recent advances in immunology have demonstrated the importance of local interactions between antigen presenting cells and effector cells such as natural killer cells and T-lymphocytes for an effective immune reaction

against tumors [61]. Interferons stimulate such interactions, while interleukins play a central role in the activation of NK cells and T-lymphocytes. Interferons were investigated as potential anticancer agents because of their antiproliferative and cytotoxic effects, their ability to activate specific components of the immune system and their relatively modest toxicities. Increasing biological evidence supports the hypothesis that tumor-generated chemokines provide more than simply angiogenic signals. Tumor-derived chemokines may potentially act as inhibitors of anti-tumor immune responses as well as autocrine growth factors for the tumor. All these chemokines activating activities of *A. subrufescens* remain to be completely evaluated both in animal model and in real clinical practice. However, immunologically active glucans are (1-3)- β -D-linked glucose polymers, which occur as a primary component in the cell walls of bacteria and fungi or are secreted extracellularly by various fungi, and actually seem the most important active substance.

EFFECTS ON INFECTION AND ALLERGY

There are a few studies in the anti-allergic test of *A. subrufescens* extract. Hetland et al found that an AbM-based extract (AndoSan), also containing the medicinal *Basidiomycetes* mushrooms *Hericium erinaceum* (15%) and *Grifola frondosa* (3%), given orally increased survival from bacterial sepsis in mice inoculated i.p. a day afterward with pneumococci [62] or fecal bacteria [63]. The mixed mushroom extract also protected against IgE-mediated allergy in a mouse model when given p.o. either before or after ovalbumin s.c. sensitization of the animals [64]. In supernatants of cultured spleen cells from the sacrificed *A. subrufescens* treated mice, there was an increased T-helper cell response relative to the allergy-inducing Th2 response. The observation fits with the reduced specific serum IgE levels in these animals and shows that also adaptive immunity is engaged by the mushroom. Since the original Th1/Th2 dichotomy [65] says that the antitumor and anti-infection Th1 response is inversely related to the Th2 response, the spleen cell finding above also helps explain the concomitant antiallergic, antitumor, and anti infection effects of *A. subrufescens*.

A. subrufescens extract has also shown to have an antidiabetic activity in diabetic rats [58, 66, 67]. Purified β -glucan from this mushroom was shown to have anti-hyperglycemic, anti-hyper

triglyceridemic, anti-hypercholesterolemic and anti-arteriosclerotic activities indicating overall anti-diabetic activity [58, 66] which was also confirmed in β -glucan removed semi purified fractions of *A. subrufescens* [67]. An ethyl acetate fraction of hot-water extract from this fungus was tested on Streptozotocin-induced diabetic rats. Hypoglycemic action indicated the fungus could be useful in the treatment of diabetes mellitus [67].

COMPARISON OF A. SUBRUFESCENS EXTRACTS

There are many different *A. subrufescens* extracts available. Glucans, one of the most active and beneficial components of *A. subrufescens*, are known to augment immune responses against viral and bacterial infections, as well as against cancer [68]. It is important to point out that not all available *A. subrufescens* extracts give the same result because they are prepared by using different mushroom strains and in accordance to different protocols. Latest reports show that there are various compositions of beta-glucans in *A. subrufescens* extracts [69] and the concentration of active ingredients in each component depends on the methods of extraction [67, 52] and on the substrate (rotting woods) they are grown on.

A scientific study compared the efficacy of the leading products available in the market, revealing extracts with the strongest anti-infection properties. In order to evaluate antibacterial efficacy of *A. subrufescens* extracts, five *A. subrufescens* products described as A, B, C, D, E were compared in a mouse model for deadly pneumococcal (Gram-positive) sepsis. The day before the sepsis was induced, the mice received similar volumes of *A. subrufescens* extracts orally: Extract described as A, which was a mixture of 82% *A. subrufescens*, 15% *Herichium erinaceum* and 3% *Grifola frondosa*, all members of the Basidiomycetes mushroom family, appeared to be the only one which had a statistically significant protective effect [68]. Extract A was the most effective in reducing the number of bacteria in the blood of the infected mice and increasing the survival rate of the animals. In another study, using Gram-negative bacteria in mice, the efficacy of *A. subrufescens* extract in decreasing bacteremia and increasing survival rate was confirmed [70]. One may speculate whether this is due to the presence of additional biological components and synergies with the two other Basidiomycetes mushrooms

ingredients as well as the protocols for cultivation and processing methods [68]. Extract A currently represents the AndoSan™ product, which appeared to be the only one that gave a significant protection to overcome deadly bacterial sepsis. Therefore, this particular mushroom extract was chosen for studies in other animal models and clinical studies (allergy, HCV infection, IBD, multiple myeloma, colon cancer). Hence, it may be a choice for prevention or treatment of different illnesses as an adjuvant.

TOXICOLOGICAL PROBLEMS

Many researchers have studied *Agaricus subrufescens*, as well as other medicinal mushrooms for close to 50 years. Although eating cultivated mushrooms or their extracts is thought to provide medicinal and other benefits, there are few studies on the safety of this practice. *Agaricus subrufescens* has been consumed by human for decades and has not been reported to be directly toxic or carcinogenic to humans. Nevertheless, we need to be cautious and consider if there are any deleterious effects from eating *A. subrufescens*. The content of poisonous microelements in fruiting bodies of this fungus has been reported. The content of Cobalt (Co), Molybdenum (Mo), Selenium (Se), Vanadium (V) are under detectable limits which are about 0.1–0.2 mg/kg of dry matter. However, the detectable amount of cadmium (Cd) is about 2–17 mg/kg of dry matter. The major concern over the use of *A. subrufescens* is the problem of the hydrazine content. *A. subrufescens* has been studied and assessed for possible side-effects of agaritine and its derivatives [26, 27] as these are suspected to be genotoxic and possible carcinogenic or tumorigenic agents. This molecule is thought to be capable of binding to the DNA of organs after administration to mice models [72]. The genotoxicity of agaritine is however, very limited. The cumulative lifespan of cancer risk obtained from agaritine consumption is probably estimated at 10^{-5} . The beneficial or toxicological effect of a bioactive substance often depends on its concentration; it will occasionally have beneficial properties at low concentrations but could be toxic at high concentrations. However, to ensure the safety of long-term using of *A. subrufescens*, further research may be required to find the optimal method to remove or reduce the content of agaritine in *A. subrufescens* extracts [73]. Further toxicology studies still need to completely confirm the safety of the use of *A. subrufescens*.

CONCLUSIONS

The aim of present review is to outline past and current major therapeutic interest and pharmacology of medicinal mushroom and their use in human healthcare. The broad spectrum of biological activities from mushrooms suggest further screening and research in that promising field of health care substances. They not only cure but have also important prophylactic properties. Mushroom metabolites defining new generation of pharmacologically active compound, should definitely help fill some of the weaknesses of current therapeutic arsenal and develop it against present and future therapeutic challenges. This mushroom with high medicinal value; used successfully in cancer therapy, chronic inflammation, diabetes, infections (HIV, fungus, bacteria), immune system disorder and possess anti-oxidant properties. Safety issues in particular should focus on the toxicity and carcinogenicity of agaritine and its derivatives in this mushroom. It would be beneficial to the success of *A. subrufescens* if it was shown not to give rise to any toxicological effects. *A. subrufescens* should be an excellent future alternative medicine.

REFERENCE

- [1] Manzi P, Gambelli L, Marconi S, Vivanti V, Pizzoferrato L. Nutrients in edible mushroom: An inter-species comparative study. *Food Chem.*, 65:477-482, 1999.
- [2] Wasser SP, Didukh MY, de Amazonas MAL, et al. (2002). Is a widely cultivated culinary-medicinal royal sun *Agaricus* (the Himematsutake Mushroom) indeed *Agaricus blazei* Murrill?. *Int. J. Med. Mush.* 4:267-290.
- [3] Kerrigan RW (2005). *Agaricus subrufescens*, a cultivated edible and medicinal mushroom, and its synonyms. *Mycologia.* 97:12-24.
- [4] Pilát A. (1951). *The bohemian species of the genus Agaricus*. Prague, 142 pp.
- [5] Takaku T, Kimura Y, Okuda H (2001). Isolation of an antitumor compound from *Agaricus blazei* Murrill and its mechanism of action. *American Society for Nutritional Sciences.* 131:1409-1413.
- [6] Kerrigan RW. 1982. The genus *Agaricus* in coastal California. (Master's Thesis) San Francisco State University. 80 p.
- [7] Tu C-C, Lin C-H. 1981. *Agaricus subrufescens* [sic] Peck, a new mushroom with potential cultivability and commercial value. *Taiwan Mush* 5:85-89.
- [8] Peterson KR, Desjardin DE, Hemmes DE. 2000. Agaricales of the Hawaiian Islands. 6. Agaricaceae I: Agariceae: *Agaricus* and *Melanophyllum*. *Sydowia* 52 (2):204-257.
- [9] Firenzuoli F, Gori L, Lombardo G., 2008. The medicinal mushroom *Agaricus blazei* Murrill: Review of literature and pharmaco-toxicological problems. *Advance Access Publication* 27, 3-15.
- [10] Wisitrasameewong K, Karunarathna S.C, Thongklang N, Zhao R. et al. 2011. *Agaricus subrufescens*: New to Thailand. *Chiang Mai Journal of Science* (In press).
- [11] Peck CH. (1893). "Report of the Botanist (1892)". *Annual Report on the New York State Museum of Natural History* 46: 85-149.
- [12] Firenzuoli F, Gori L, Lombardo G (2007). The Medicinal Mushroom *Agaricus blazei* Murrill: Review of Literature and Pharmaco-Toxicological Problems. *Evid Based Complement Alternat Med.* 5:3-15.
- [13] Wasser, S.P., 2002. Medicinal mushrooms as source of antitumor and immunomodulating polysaccharides. *Appl. Microbiol. Biotechnol.* 60: 258-274.
- [14] Angeli JP, Ribeiro LR, Gonzaga ML, et al. (2006). Protective effects of beta-glucan extracted from *Agaricus brasiliensis* against chemically induced DNA damage in human lymphocytes. *Cell Biol Toxicol.* 22:285-291.
- [15] Yu CH, Kan SF, Shu CH, et al. (2009). Inhibitory mechanisms of *Agaricus blazei* Murrill on the growth of prostate cancer in vitro and in vivo. *J. Nutr. Biochem.* 20: 753-764.
- [16] Jumes FM, Lugarini D, Pereira AL, et al. (2010). Effects of *Agaricus brasiliensis* mushroom in Walker-256 tumor-bearing rats. *Can. J. Physiol. Pharmacol.* 85 (1): 21-27.
- [17] Fujimiya Y, Suzuki Y, Oshiman KI, et al. (1998). Selective tumoricidal effect of soluble proteoglycan extracted from the basidiomycete, *Agaricus blazei* Murrill, mediated via natural kill cell activation and apoptosis.
- [18] Gonzaga ML, Bezerra DP, Alves AP, et al. (2009). In vivo growth-inhibition of Sarcoma 180 by an alpha-(1, 4)-glucan-beta-(1, 6)-glucan-protein complex polysaccharide obtained from *Agaricus blazei* Murrill. *J Nat Med.* 63:32-40.
- [19] Mizuno T, Hagiwara T, Nakamura Tv et al. (1990). Antitumor activity and some

- properties of water-soluble polysaccharides from "Himematsutake", the fruiting body of *Agaricus blazei* Murrill. *Agri. Biol. Chem.*, 54: 2897-2906.
- [20] Hikichi M, Hiroe E, Okubo S (1999). Protein polysaccharide 0041. European Patent 0939082, 9 January 1999.
- [21] Tsuchida H, Mizuno M, Taniguchi Y, et al. (2001) Glucomannan separated from *Agaricus blazei* mushroom culture and antitumor agent containing as active ingredient. Japanese Patent 11-080206.
- [22] Mizuno T, Hagiwara T, Nakamura T, et al. (1990). Antitumor activity and some properties of water-soluble polysaccharides from Himematsutake, the fruiting body of *Agaricus blazei* Murrill. *Agri. Biol. Chem.* 54: 2889- 2896.
- [23] Kawagishi H, Kanao T, Inagaki R, et al. (1990). Formolysis of a potent antitumor (1-6)-b-D-glucan-protein complex from *Agaricus blazei* fruiting bodies and antitumor activity of the resulting products. *Carbohydr. Polym.* 12:393-403.
- [24] Cho SM., Park JS, Kim KP, et al. (1999). Chemical features and purification of immunostimulating polysaccharides from the fruiting bodies of *Agaricus blazei*. *Korean J. Microbiol* 27:170-174.
- [25] Angeli JP, Ribeiro LR, Gonzaga ML, et al. (2006). Protective effects of beta-glucan extracted from *Agaricus brasiliensis* against chemically induced DNA damage in human lymphocytes. *Cell Biol Toxicol.* 22:285-291.
- [26] Stijve T., Pittet A., Andrey D et al. (2003). Potential toxic constituents of *Agaricus brasiliensis* (*A. Blazei* ss. Heinem.), as compared to other cultivated and wild-growing edible mushrooms. *Deutsche Lebensmittel-Rundschau* 99:475-481.
- [27] Nagaoka MH, Nagaoka H, Kondo K et al. (2006). Measurement of a genotoxic hydrazine, agaritine, and its derivatives by HPLC with fluorescence derivatization in the *Agaricus* mushroom and its products. *Chem. Pharm. Bull. (Tokyo)*. 54:922-924.
- [28] Itoh H, Ito H, Hibasami H (2008). Blazein of a new steroid isolated from *Agaricus blazei* murrill (himematsutake) induces cell death and morphological change indicative of apoptotic chromatin condensation in human lung cancer LU99 and stomach cancer KATO III cells. *Oncology Reports.* 20:1359-1361.
- [29] Akiyama H, Endo M, Matsui T, et al. (2011). Agaritine from *Agaricus blazei* Murrill induces apoptosis in the leukemic cell line U937. *Biochim Biophys Acta* 1810:519-525.
- [30] Endo M, Beppu H, Akiyama H, et al. (2010). Agaritine purified from *Agaricus blazei* Murrill exerts anti-tumor activity against leukemic cells. *Biochim. Biophys. Acta* 1800:669-673.
- [31] Kimura Y, Kido T, Takaku T, et al. (2004). Isolation of an anti-angiogenic substance from *Agaricus blazei* Murrill: its antitumor and antimetastatic actions. *Cancer Sci.* 95:758-764.
- [32] Gao L, Sun Y, Chen C, et al. (2007). Primary mechanism of apoptosis induction in a leukemia cell line by fraction FA-2-b-ss prepared from the mushroom *Agaricus blazei* Murrill. *Braz. J Med Biol Res.* 40:1545-1555.
- [33] Ohno, N., Furukawa, M., Miura, N.N., Adachi, Y., Motoi, M., Yadomae, T., 2001. Antitumor-b-glucan from the cultured fruiting body of *Agaricus blazei*. *Biological and Pharmaceutical Bulletin* 24 (7), 820-828.
- [34] H. Kawagishi, K. Inagaki, T. Kanao, T. Mizuno, K. Shimura, H. Ito, T. Hagiwara, T. Hakamura Fractionation and antitumor activity of the water-soluble residue of *Agaricus blazei* fruiting bodies *Carbohydrate Research*, 186 (1989), pp. 267-274.
- [35] Itoh, H., Ito, H., Amano, H., Noda, H., 1994. Inhibitory action of a (1-6)-beta-D-glucan-protein complex (F III-2-b) isolated from *Agaricus blazei* Murrill ("himematsutake") on Meth A fibrosarcoma-bearing mice and its antitumor mechanism. *The Japanese Journal of Pharmacology* 66, 265-271.
- [36] Ito, H., Shimura, K., Itoh, H., Kawade, M., 1997. Antitumor effects of a new polysaccharide-protein complex (ATOM) prepared from *Agaricus blazei* (Iwade strain 101) "Himematsutake" and its mechanisms in tumor-bearing mice. *Anticancer Research* 17, 277-284.
- [37] Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F (1969) Inhibition of mouse sarcoma 180 by polysaccharides from *Lentinus edodes* (Berk.) Sing. *Nature* 222:687-688.
- [38] Chihara G, Hamuia J, Maeda YY, Arai Y, Fukuoka F (1970) Fractionation and purification of the polysaccharides with marked antitumor activity especially lentinan from *Lentinus edodes*. *Cancer Res* 30:2776-2781.

- [39] Wasser SP (2010a) Medicinal mushroom science: history, current status, future trends, and unsolved problems. *Int J Med Mushrooms* 12(1):1-16.
- [40] Smith JE, Sullivan R, Rowan NJ (2003) The role of polysaccharides derived from medicinal mushrooms in cancer treatment programs: current perspectives (review). *Int J Med Mushrooms* 5:217-234.
- [41] Gao Y, Zhou Sh, Huang M, Xu A (2003) Antibacterial and antiviral value of the genus *Ganoderma* P. Karst. Species (Aphyllorphomycetidae): a review. *Int J Med Mushrooms* 5:235-246.
- [42] Gao Y, Lan J, Dai X, Ye J, Zhou Sh (2004) A phase I/II study of Ling Zhi mushroom *Ganoderma lucidum* (W.Curt.:Fr.) Lloyd (Aphyllorphomycetidae) extract in patients with type II diabetes mellitus. *Int J Med Mushrooms* 6:96-107.
- [43] Sullivan R, Smith JE, Rowan NJ (2006) Medicinal mushrooms and cancer therapy. Translating a traditional practice into Western medicine. *Perspect Biol Med* 49:159-170.
- [44] Radic N, Jevnikar Z, Obermajer N, Kristl J, Kos J, Pohleven F, Strukelj B (2010) Influence of culinary-medicinal maitake mushroom, *Grifola frondosa* (Dicks:Fr.) S.F. Gray (Aphyllorphomycetidae) polysaccharides on gene expression in Jurkat T lymphocytes. *Int J Med Mushrooms* 12:245-256.
- [45] Kim, C.F., Jiang, J.J., Leung, K.N., Fung, K.P., Lau, C.B.S., 2009. Inhibitory effect of *Agaricus blazei* extracts on human myeloma cells. *Journal of Ethnopharmacology* 122, 320-326.
- [46] Gonzaga, M.L.C., Ricardo, N.M.P.S., Heatley, F., Soares, S.D.A., 2005. Isolation and characterization of polysaccharides from *Agaricus blazei* Murrill. *Carbohydrate Polymers* 60, 43-49.
- [47] Mizuno T (1999) The extraction and development of antitumor-active polysaccharides from medicinal mushrooms in Japan (Review). *Int J Med Mushrooms* 1:9-29.
- [48] Gao Y, Zhou S, Chen G, Dai X, Ye JA (2002) Phase I/II study of a *Ganoderma lucidum* extract (Ganopoly) in patients with advanced cancer. *Int J Med Mushrooms* 4:207-214.
- [49] Zhang M, Cui SW, Cheung PCK, Wang Q (2007) Antitumor polysaccharides from mushrooms: a review on their isolation, structural characteristics and antitumor activity. *Trends Food Sci Technol* 18:4-19.
- [50] Angeli JP, Ribeiro LR, Bellini MF, Mantovani MS. Beta-glucan extracted from the medicinal mushroom *Agaricus blazei* Prevents the genotoxic effects of benzo [a] pyrene in the human hepatoma cell line HepG2. *Arch Toxicol* 2009; 83 (1): 81-86.
- [51] Delmanto RD, Lima PL, I sucked MM, Eira AF, Salvadori DM, altered within G et al. Antimutagenic effect of *Agaricus blazei* Murrill mushroom on the genotoxicity induced by Cyclophosphamide. *Mutat Res* 2001; 496: 15-21.
- [52] Sorimachi K, Akimoto K, Inafuku K, Okubo A, Yamazaki S. Secretion of TNF-g, IL-8 and nitric oxide by macrophages activated with *Agaricus blazei* Murrill fractions in vitro. *Cell Struct Funct* 2001; 26:103-8.
- [53] Sorimachi K, Akimoto K, Hattori Y, Ieiri T, Niwa A. Secretion of TNF-a, IL-8 and nitric oxide by macrophages activated with polyanions, and involvement of interferon-g in the regulation of cytokine secretion. *Cytokine* 1999; 11:571-8.
- [54] Sorimachi K, Akimoto K, Niwa A, Yasumura Y. Delayed cytotoxic effect of lignin derivatives on virally transformed rat fibroblasts. *Cancer Detect Prev* 1997; 21:111-7.
- [55] Sorimachi K, Niwa A, Yamazaki S, Toda S, Yasumura Y. Antiviral activity of water-solubilized lignin derivatives in vitro. *Agric Biol Chem* 1990; 54:1337-9.
- [56] Shimizu S, Kitada H, Yokota H, Yamakawa J, Murayama T, Sugiyama K, et al. Activation of the alternative complement pathway by *Agaricus blazei* Murrill. *Phytomedicine* 2002; 9:536-45.
- [57] Kasai, H., He, L.M., Kawamura, M., Yang, P.T., Deng, X.W., Munkanta, M., Yamashita, A., Terunuma, H., Hirama, M., Horiuchi, I., Natori, T., Koga, T., Amano, Y., Yamaguchi, N., Ito, M., 2004. IL-12 production induced by *Agaricus blazei* fraction H (ABH) involves Toll-like Receptor (TLR). *Evidence-based Complementary and Alternative Medicine* 1 (3), 259-267.
- [58] Kim GY, Lee MY, Lee HJ, et al. (2005). Effect of water-soluble proteoglycan isolated from *Agaricus blazei* on the maturation of murine bone marrow-derived dendritic cells. *Int. Immunopharmacol.* 5:1523-1532.

- [59] Førland DT, Johnson E, Saetre L, et al. (2011). Effect of an extract based on the medicinal mushroom *Agaricus blazei* Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn's disease. *Scand. J. Immunol.* 73:66-75.
- [60] Johnson E, Førland DT, Saetre L, et al. (2009). Effect of an extract based on the medicinal mushroom *Agaricus blazei* murill on release of cytokines, chemokines and leukocyte growth factors in human blood ex vivo and in vivo. *Scand. J. Immunol.* 69:242-250.
- [61] Cooper EL. Commentary on CAM and NK Cells by Kazuyoshi Takeda and Ko Okumura. *eCAM* 2004;1:29-34.
- [62] S. Bernardshaw, E. Johnson, and G.Hetland, "An extract of the mushroom *Agaricus blazei* Murill administered orally protects against systemic *Streptococcus pneumoniae* infection in mice," *Scandinavian Journal of Immunology*, vol. 62, no. 4, pp. 393-398, 2005.
- [63] S. Bernardshaw, G. Hetland, B. Grinde, and E. Johnson, "An extract of the mushroom *Agaricus blazei* Murill protects against lethal septicemia in a mouse model of fecal peritonitis," *Shock*, vol. 25, no. 4, pp. 420-425, 2006.
- [64] L. K. Ellertsen and G. Hetland, "An extract of the medicinal mushroom *Agaricus blazei* Murill can protect against allergy," *Clinical and Molecular Allergy*, vol. 7, article no. 6, 2009.
- [65] S. Romagnani, "The Th1/Th2 paradigm," *Immunology Today*, vol. 18, pp. 263-266, 1997.
- [66] Kim, Y.W., Kim, K.H., Choi, H.J., Lee, D.S., 2005b. Anti-diabetic activity of b-glucans and their enzymatically hydrolyzed oligosaccharides from *Agaricus blazei*. *Biotechnology Letters* 27, 483-487.
- [67] Oh, T.W., Kim, Y.A., Jang, W.J., Byeon, J.I., Ryu, C.H., Kim, J.O., Ha, Y.L., 2010. Semipurified fractions from the submerged-culture broth of *Agaricus blazei* Murrill reduced blood glucose levels in streptozotocin-induced diabetic rats. *Journal of Agricultural and Food Chemistry* 58, 4113-4119.
- [68] Hetland G, Johnson E, Lyberg T, Bernardshaw S, Tryggstad AMA, Grinde B. Effects of the medicinal mushroom *Agaricus blazei* murill on immunity, infection and cancer. *Scand J Immunol* 2008; 68:363-370.
- [69] Volman JJ, Helsper JP, Wei S, Baars JJ, van Griensven LJ, Sonnenberg AS, Mensink RP, Plat J. Effects of mushroom-derived beta-glucan-rich polysaccharide extracts on nitric oxide production by bone marrow-derived macrophages and nuclear factor-kappaB transactivation in Caco-2 reporter cells: can effects be explained by structure? *Mol Nutr Food Res* 2010; 54:268-276.
- [70] Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. *Annu Rev Immunol* 2004; 22:891-928.
- [71] Gyorfı, J., Geo" sel, A., Vetter, J., 2010. Mineral composition of different strains of edible medicinal mushroom *Agaricus subrufescens* Peck. *Journal of Medicinal Food* 13 (6), 1510-1514.
- [72] Shephard, S.E., Schlatter, C., 1998. Covalent binding of agaritine to DNA in vivo. *Food Chemical Toxicology* 36, 971-974.
- [73] Sorimachi, K., Nakamoto, T., 2011. Alternative medicine safety: *Agaricus blazei* and propolis. *Combinatorial Chemistry and High Throughput Screening* 14 (7), 616-621.